섬유주세포에서 베바시주맙과 라니비주맙이 일산화질소합성효소의 발현에 미치는 영향

Effect of Bevacizumab and Ranibizumab on the Expression of eNOS in Trabecular Meshwork Cells

Purpose: To compare the effects of bevacizumab and ranibizumab on the expression of eNOS in cultured human trabecular meshwork cells (HTMC). Methods: Primarily cultured HTMC were exposed to 0.5 mg/mL bevacizumab and ranibizumab using 1% serum-containing media for 30 minutes. Expression of eNOS mRNA was assessed with RT-PCR. Additionally, after exposure to 20 ng/mL of vascular endothelial growth factor (VEGF) and 0.5 mg/mL bevacizumab and ranibizumab, the production of nitric oxide was assessed with Griess assay. Results: VEGF increased the production of nitric oxide in HTMC. Bevacizumab and ranibizumab decreased the expression of eNOS mRNA and production of nitric oxide (<em>p</em> &lt; 0.05) in HTMC. The decrease in eNOS mRNA expression and production of nitric oxide was not significant between bevacizumab and ranibizumab (<em>p</em> &gt; 0.05). Conclusions: In HTMC, both bevacizumab and ranibizumab decreased the expression of eNOS mRNA with no significant difference observed between the two drugs. J Korean Ophthalmol Soc 2014;55(8):1208-1212